Prometheus Biosciences Reports First Quarter 2021 Financial Results and Provides a Corporate Update
May 13, 2021 16:01 ET
|
Prometheus Biosciences
-PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohn’s Disease in 3Q 2021- -Launched Prometheus Enroll360™, a global patient recruitment...